Status and phase
Conditions
Treatments
About
ZX-101A-201 is a phase I, open-label, multicenter study which includes dose escalation and dose expansion of ZX-101A. It is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and antitumor activity of ZX-101A in patients with advanced solid tumors.
Full description
Phase I includes two parts: dose escalation and dose expansion.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
76 participants in 5 patient groups
Loading...
Central trial contact
Li Luo; Shun Yang
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal